{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:13:55Z","timestamp":1783030435477,"version":"3.54.6"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijcard.2024.131894","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T16:15:32Z","timestamp":1709396132000},"page":"131894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation"],"prefix":"10.1016","volume":"404","author":[{"given":"Reinhold","family":"Kreutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Enders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abdelgawwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"H\u00e4ckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Schmedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Bonnemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2021","key":"10.1016\/j.ijcard.2024.131894_bb0005","first-page":"373","article-title":"ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"issue":"2021","key":"10.1016\/j.ijcard.2024.131894_bb0010","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2024.131894_bb0015","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.131894_bb0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.131894_bb0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.131894_bb0030","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.131894_bb0035","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00392-017-1098-x","article-title":"Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study","volume":"106","author":"Hohnloser","year":"2017","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131894_bb0040","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1160\/TH17-10-0733","article-title":"Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation","volume":"118","author":"Hohnloser","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2024.131894_bb0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1055\/s-0039-1683422","article-title":"Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation","volume":"119","author":"Hohmann","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2024.131894_bb0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.131894_bb0055","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.131894_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/STROKEAHA.114.006881","article-title":"Risk of thromboembolic events in atrial fibrillation with chronic kidney disease","volume":"46","author":"Zeng","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2024.131894_bb0065","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.mayocp.2018.06.018","article-title":"Influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of non-vitamin K antagonist oral anticoagulants","volume":"93","author":"Weir","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ijcard.2024.131894_bb0070","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/europace\/euv202","volume":"17","author":"Boriani","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2024.131894_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease","volume":"223","author":"Weir","year":"2020","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2024.131894_bb0080","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial","volume":"65","author":"B\u00f6hm","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131894_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2024.131894_bb0090","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of atrial fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2024.131894_bb0095","doi-asserted-by":"crossref","first-page":"O78","DOI":"10.1093\/eurheartj\/suaa182","article-title":"Concomitant diabetes with atrial fibrillation and anticoagulation management considerations","volume":"22","author":"Kreutz","year":"2020","journal-title":"Eur. Heart J. Suppl."},{"key":"10.1016\/j.ijcard.2024.131894_bb0100","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/europace\/euab184","article-title":"Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus","volume":"12","author":"Fauchier","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2024.131894_bb0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131894_bb0110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/pds.3895","article-title":"Characteristics and external validity of the German health risk institute (HRI) database","volume":"25","author":"Andersohn","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ijcard.2024.131894_bb0115","article-title":"Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - a retrospective cohort study","volume":"23","author":"Bonnemeier","year":"2019","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"10.1016\/j.ijcard.2024.131894_bb0120","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehp318","article-title":"Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists","volume":"30","author":"Lip","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131894_bb0125","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","article-title":"Development of a claims-based frailty indicator anchored to a well-established frailty phenotype","volume":"55","author":"Segal","year":"2017","journal-title":"Med. Care"},{"key":"10.1016\/j.ijcard.2024.131894_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"key":"10.1016\/j.ijcard.2024.131894_bb0135","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131894_bb0140","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131894_bb0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.131894_bb0150","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2015.07.006","volume":"170","author":"Bansilal","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2024.131894_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijcard.2020.01.009","article-title":"Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial","volume":"304","author":"Plitt","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131894_bb0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvu024","article-title":"Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial","volume":"1","author":"Ezekowitz","year":"2015","journal-title":"Eur. Heart J. Cardiovas. Pharmacother."},{"key":"10.1016\/j.ijcard.2024.131894_bb0165","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2024.131894_bb0170","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/STROKEAHA.119.025554","article-title":"Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin","volume":"51","author":"Alberts","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2024.131894_bb0175","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2024.131894_bb0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12933-021-01250-5","article-title":"Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin","volume":"20","author":"Coleman","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2024.131894_bb0185","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","article-title":"Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation","volume":"68","author":"Chan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131894_bb0190","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2024.131894_bb0195","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12872-017-0672-5","article-title":"Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation","volume":"17","author":"Norby","year":"2017","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ijcard.2024.131894_bb0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","article-title":"A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants","volume":"3","author":"Halvorsen","year":"2017","journal-title":"Eur. Heart J. Cardiovas. Pharmacother."},{"key":"10.1016\/j.ijcard.2024.131894_bb0205","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","article-title":"Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients","volume":"30","author":"Lalibert\u00e9","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ijcard.2024.131894_bb0210","first-page":"10","article-title":"Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure, ESC","volume":"6","author":"Martinez","year":"2019","journal-title":"Heart Fail."},{"key":"10.1016\/j.ijcard.2024.131894_bb0215","first-page":"907","article-title":"Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study","volume":"38","author":"Staerk","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131894_bb0220","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal outcomes in anticoagulated patients with atrial fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131894_bb0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2018.12.010","article-title":"Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: a pooled analysis of randomized controlled trials and real-world studies","volume":"174","author":"Zhang","year":"2019","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ijcard.2024.131894_bb0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ehjqcco\/qcz047","article-title":"Rivaroxaban versus warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes","volume":"6","author":"Hernandez","year":"2019","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"10.1016\/j.ijcard.2024.131894_bb0235","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/nu12010100","article-title":"Pharmacological and nutritional modulation of vascular calcification","volume":"12","author":"Vossen","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.ijcard.2024.131894_bb0240","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.3390\/nu7115479","article-title":"New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs)","volume":"7","author":"van Gorp","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.ijcard.2024.131894_bb0245","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1182\/blood-2010-01-264598","article-title":"Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans","volume":"115","author":"Rennenberg","year":"2010","journal-title":"Blood"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324003401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324003401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:53:30Z","timestamp":1712364810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324003401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":49,"alternative-id":["S0167527324003401"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131894","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"131894"}}